The Next Decade of Medical Device Innovation: Why Regulatory Science Must Evolve With Technology

On September 25, 2026, the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) and the Medical Device Innovation Consortium (MDIC) convened a public meeting titled “Regulatory Science Innovations Catalyzing Medical Device Development.” The meeting brings together representatives from government, industry, academia, and patient advocacy to examine an important question for the medical device sector:

What regulatory science capabilities will be needed to support the next generation of medical technologies?

For medical device companies, this discussion is worth watching closely. It highlights areas where technology, evidence generation, product development, and regulatory strategy are increasingly intersecting—and where early planning may become even more important.

Why FDA and MDIC Are Having This Discussion

According to FDA, the purpose of the meeting is to advance regulatory science supporting breakthrough devices and disruptive medical device technologies through multi-stakeholder dialogue. The initiative is intended to help inform CDRH's long-term research priorities and strategic planning and to identify regulatory science challenges anticipated to affect medical device development over the next decade.

FDA identified two principal objectives:

• Gather stakeholder perspectives on emerging technologies, changing clinical scenarios, and anticipated regulatory science needs.

• Identify critical regulatory science gaps that could potentially impede development of safe and effective novel and disruptive medical devices.

The September 25 meeting does not establish new regulatory requirements or announce a new FDA guidance. Rather, it is a forward-looking discussion about where regulatory science may need to advance as medical technologies and their environments of use continue to change.

Five Areas Medical Device Companies Should Be Watching

FDA's meeting agenda and pre-meeting materials point to several areas that could have significant implications for future medical device development.

1. Digital Health and Increasingly Complex Technologies

Digital technologies are changing both medical devices and the healthcare environments in which they operate. FDA's agenda specifically identifies digital health among the areas being considered as part of the discussion about future regulatory science needs.

As technologies become increasingly software-enabled, connected, adaptive, or data-dependent, development teams may need to think differently about how they demonstrate safety, effectiveness, and performance throughout the product lifecycle.

For companies developing these technologies, regulatory strategy should therefore be integrated with product and evidence strategy early in development—not treated solely as a submission-stage activity.

2. Cybersecurity as a Product Lifecycle Consideration

Cybersecurity is another topic specifically included in FDA's September 25 program.

Connected medical technologies can introduce risks that evolve after a device enters the market. Cybersecurity therefore intersects with product design, risk management, software development, verification and validation, post-market monitoring, and lifecycle management. The broader lesson for development organizations is that emerging regulatory challenges increasingly cross traditional functional boundaries.

Regulatory, Quality, R&D, Clinical, Software, Operations, and other relevant functions may need to align much earlier in the development process.

3. The Growing Role of Computational and In-Silico Methods

FDA's agenda also identifies in-silico tools as an area for discussion.

Computational modeling and simulation have the potential to complement traditional approaches to device development and evidence generation. FDA's pre-meeting materials specifically ask stakeholders to consider how tools ranging from bench testing and non-animal approaches to computational modeling and simulation could address limitations in existing evaluation methods.

The important question is not simply whether new tools are available. It is whether the evidence generated by those tools is sufficiently appropriate, reliable, and scientifically justified for the intended regulatory purpose. That places increasing importance on planning the evidence strategy early and understanding how each element of testing supports the overall demonstration of device safety and performance.

4. Non-Animal Methods and Evolving Evaluation Tools

Non-animal methods are also explicitly included in the meeting agenda.

FDA is asking stakeholders to consider where current approaches for assessing device safety, effectiveness, and performance may have limitations and where emerging evaluation tools could help address those gaps.

For manufacturers, this reinforces the importance of maintaining a scientifically justified testing strategy rather than assuming that historical testing approaches will automatically remain the most appropriate approach for every new technology.

As evaluation methods evolve, organizations should continue assessing whether their verification, validation, biological evaluation, preclinical, and other evidence-generation strategies remain appropriate for the device, its risks, and its intended use.

5. Clinical Evidence for Next-Generation Devices

Perhaps one of the most important questions raised in FDA's pre-meeting materials concerns clinical evidence. FDA asks how meaningful clinical evidence can continue to be generated as devices become more novel and complex, noting that traditional study designs and endpoints may not always be well suited to capture what matters most to patients. The agency is seeking stakeholder perspectives on challenges involving clinical study design, endpoints, data collection, and evidence generation for next-generation technologies.

This is particularly important because clinical strategy should not exist independently from regulatory and product-development strategy. Decisions involving intended use, indications, claims, endpoints, patient populations, device design, risk, and evidence generation can ultimately affect one another.

Medical Devices Are Also Moving Beyond Traditional Clinical Settings

Another important theme in FDA's pre-meeting questions is the changing environment in which medical devices are used. FDA notes that devices are increasingly being used outside traditional clinical environments, including in homes and community settings and in care models where clinicians may not be immediately present. That shift raises practical questions about device performance across different users and environments, usability, error detection, patient and caregiver interaction, and the ability to generate evidence that reflects real-world conditions.

For development teams, the environment of use should therefore be considered early—not simply during final usability validation. Human factors, risk management, clinical strategy, labeling, training, product requirements, and post-market planning may all be affected by where and how a device will ultimately be used.

What This Means for Medical Device Organizations

The most important takeaway from the FDA-MDIC discussion may be broader than any individual technology.

Regulatory strategy is becoming increasingly interconnected with the entire product development lifecycle. Organizations developing innovative medical technologies should consider several questions early:

Are we identifying regulatory uncertainty early enough?

Novel technology can introduce questions for which established regulatory pathways, testing approaches, standards, or precedent may not provide a complete answer.

Does our evidence strategy reflect the technology we are actually developing?

Bench, preclinical, computational, clinical, human factors, and real-world evidence should form a coherent strategy rather than a collection of independent activities.

Are Regulatory, Quality, Clinical, R&D, and Operations aligned?

Many late-stage regulatory and validation problems originate from decisions made much earlier in development. Cross-functional alignment can help identify those issues before they become schedule, compliance, or submission risks.

Are we designing only for today's expectations—or also anticipating where the regulatory environment is heading?

Companies do not need to predict future regulations. They should, however, monitor regulatory science developments and understand where agencies are signaling areas of scientific uncertainty or future focus.

An Opportunity for Industry Participation

FDA has also opened a public docket associated with the September 25 meeting.

The agency is seeking comments from stakeholders regarding emerging device technologies and critical regulatory science gaps that could affect medical device development.

The docket, FDA-2026-N-8563, is scheduled to remain open for 60 days following the meeting and close on November 24, 2026. For organizations working at the frontier of medical technology, this provides an opportunity to contribute practical experience regarding scientific or regulatory challenges that may affect future device development.

Building Regulatory Strategy Into Innovation

Innovation and regulatory compliance should not be viewed as competing objectives.

For companies developing increasingly complex technologies, a well-integrated regulatory strategy can help clarify the evidence needed to support development decisions, identify uncertainty earlier, coordinate cross-functional activities, and reduce avoidable downstream surprises.

At OneGlobal Trinity M Consulting, we support medical device, pharmaceutical, and biotechnology organizations across complex product development and compliance programs, helping teams connect regulatory strategy, quality and compliance, clinical activities, product development, and program execution. As regulatory science evolves, successful organizations will need more than an understanding of individual regulatory requirements. They will need an integrated strategy connecting science, evidence, compliance, execution, and the product lifecycle.

About OneGlobal Trinity M Consulting

OneGlobal Trinity M Consulting provides consulting support to medical device, pharmaceutical, and biotechnology organizations navigating complex regulatory, quality, clinical, product development, and program execution challenges.

Need support with a complex regulatory, quality, clinical, or product development program? Contact OneGlobal Trinity M Consulting to discuss how we can support your organization.